162 related articles for article (PubMed ID: 21456384)
21. Anthracyclines, HER2, and TOP2A: the verdict.
Bonnefoi HR
Lancet Oncol; 2011 Nov; 12(12):1084-5. PubMed ID: 21917520
[No Abstract] [Full Text] [Related]
22. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
23. Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Romero A; Caldés T; Díaz-Rubio E; Martín M
Clin Transl Oncol; 2012 Mar; 14(3):163-8. PubMed ID: 22374418
[TBL] [Abstract][Full Text] [Related]
24. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.
Jacot W; Fiche M; Zaman K; Wolfer A; Lamy PJ
Biochim Biophys Acta; 2013 Aug; 1836(1):146-57. PubMed ID: 23628726
[TBL] [Abstract][Full Text] [Related]
25. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Di Leo A; Isola J
Clin Breast Cancer; 2003 Aug; 4(3):179-86. PubMed ID: 14499010
[TBL] [Abstract][Full Text] [Related]
27. [Predictive factors for response to chemotherapy in breast cancers].
Miyoshi Y; Noguchi S
Nihon Rinsho; 2007 Jun; 65 Suppl 6():154-9. PubMed ID: 17682152
[No Abstract] [Full Text] [Related]
28. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase 2α status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation.
Olszewski W; Pieńkowski T; Olszewski W; Mrozkowiak A; Bauer-Kosińska B; Piaścik A; Olszewska K; Wojnowska A; Michalski W
Pol J Pathol; 2014 Dec; 65(4):283-90. PubMed ID: 25693082
[TBL] [Abstract][Full Text] [Related]
31. Role of anthracyclines in the treatment of early breast cancer.
Gianni L; Norton L; Wolmark N; Suter TM; Bonadonna G; Hortobagyi GN
J Clin Oncol; 2009 Oct; 27(28):4798-808. PubMed ID: 19687331
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
33. Expression of topoisomerase II-α in triple negative breast cancer.
Mrklić I; Pogorelić Z; Ćapkun V; Tomić S
Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):182-7. PubMed ID: 23702653
[TBL] [Abstract][Full Text] [Related]
34. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
Simon R
J Clin Oncol; 2011 Jul; 29(21):2941; author reply 2941-4. PubMed ID: 21670460
[No Abstract] [Full Text] [Related]
35. Tailored targeted therapy for all: a realistic and worthwhile objective against.
Pritchard KI
Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S8. PubMed ID: 20030883
[No Abstract] [Full Text] [Related]
36. [Medical treatment of early breast cancer: chemotherapy].
Ejlertsen B; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
[TBL] [Abstract][Full Text] [Related]
37. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F
Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383
[TBL] [Abstract][Full Text] [Related]
38. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
39. [Indications and limitations of primary systemic therapy for operable breast cancer].
Yamamoto N; Suzuki M; Tanabe N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():500-6. PubMed ID: 17682201
[No Abstract] [Full Text] [Related]
40. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
